Open-label, single dose clinical trial of scAAV9.U7.ACCA via peripheral limb vein injection for Duchenne muscular dystrophy boys who have a duplication of exon 2.

Start Date15 Jan 2020

Sponsor / Collaborator

Nationwide Children's Hospital

[+1]

100 Clinical Results associated with scAAV9.U7.ACCA

100 Translational Medicine associated with scAAV9.U7.ACCA

100 Patents (Medical) associated with scAAV9.U7.ACCA

Literatures (Medical) associated with scAAV9.U7.ACCA

01 Dec 2023·Molecular Therapy - Methods & Clinical Development

Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model

Article

Author: Lay, Jacob W ; Vetter, Tatyana A ; Rohan, Natalie L ; Bradley, Adrienne J ; Gushchina, Liubov V ; Flanigan, Kevin M ; Wein, Nicolas ; Frair, Emma C

Duchenne muscular dystrophy (DMD) is a progressive X-linked disease caused by mutations in the DMD gene that prevent the expression of a functional dystrophin protein. Exon duplications represent 6%-11% of mutations, and duplications of exon 2 (Dup2) are the most common (∼11%) of duplication mutations. An exon-skipping strategy for Dup2 mutations presents a large therapeutic window. Skipping one exon copy results in full-length dystrophin expression, whereas skipping of both copies (Del2) activates an internal ribosomal entry site (IRES) in exon 5, inducing the expression of a highly functional truncated dystrophin isoform. We have previously confirmed the therapeutic efficacy of AAV9.U7snRNA-mediated skipping in the Dup2 mouse model and showed the absence of off-target splicing effects and lack of toxicity in mice and nonhuman primates. Here, we report long-term dystrophin expression data following the treatment of 3-month-old Dup2 mice with the scAAV9.U7.ACCA vector. Significant exon 2 skipping and robust dystrophin expression in the muscles and hearts of treated mice persist at 18 months after treatment, along with the partial rescue of muscle function. These data extend our previous findings and show that scAAV9.U7.ACCA provides long-term protection by restoring the disrupted dystrophin reading frame in the context of exon 2 duplications.

100 Deals associated with scAAV9.U7.ACCA

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Muscular Dystrophy, Duchenne	Phase 2	-	Astellas Gene Therapies, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


scAAV9.U7-ACCA (ASGCT2023)	Not Applicable	Muscular Dystrophy, Duchenne	3	scAAV9.U7-ACCA	oqsjrgoykq(zsxcifrmjt) = ejhsspzegw iavuzvhsum (cgeizadldw ) View more	Positive	01 May 2023
ASGCT2022	Not Applicable	Muscular Dystrophy, Duchenne exon 2 duplications	3	scAAV9.U7-ACCA	hvmqvlenvk(xtxvvryrvg) = xmeuezsozb ukhibyxgve (bnsddppxmd ) View more	Positive	02 May 2022
NCT04240314 (ASGCT2021)	Phase 1/2	Muscular Dystrophy, Duchenne	2	scAAV9.U7-ACCA vector	darxuqncjl(clxfkzlmcu) = subtle improvements were seen in the 100 meter timed test for subject 1 (54.3% predicted to 58.8% predicted) at 6 months and 61.4% predicted at 12 months rlpmivwhah (mjvuczqagn ) View more	Positive	27 Apr 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

scAAV9.U7.ACCA

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation